Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion.

BACKGROUND Myocardial injury after ischemia and reperfusion can be attributed largely to the effects of polymorphonuclear leukocytes (PMN). The complement system plays an important role as a chemotactic agent, affecting adhesion molecule expression and neutrophil accumulation. METHODS AND RESULTS In the present study, the cardioprotective effects of C1 esterase inhibitor (C1 INH) were examined in a feline model of myocardial ischemia and reperfusion (90 minutes of ischemia followed by 270 minutes of reperfusion). C1 INH (15 mg/kg) administered 10 minutes before reperfusion significantly attenuated myocardial necrosis compared with vehicle (10 +/- 2% and 29 +/- 2% necrosis as a proportion of area at risk, respectively; P < .01). Myocardial preservation was also related to reduced plasma accumulation of creatine kinase activity. C1 INH treatment resulted in improved recovery of cardiac contractility and preservation of coronary vascular endothelial function, as assessed by relaxation in response to acetylcholine, compared with contractility and preservation of endothelial function in vehicle-treated animals (69 +/- 6% and 20 +/- 4% relaxation, respectively; P < .01). In addition, cardiac myeloperoxidase activity (an index of PMN accumulation) in the ischemic area was significantly reduced after C1 INH treatment. Furthermore, immunohistochemical analysis of ischemic-reperfused myocardial tissue demonstrated deposition of the first component of the classic complement pathway, C1q, on cardiac myocytes and coronary vessels. CONCLUSIONS Blocking of the classic complement pathway by C1 INH appears to be an effective means of preserving ischemic myocardium from reperfusion injury. The mechanism of this cardioprotective effect appears to be inhibition of PMN-endothelium interaction; this inhibition leads to preservation of normal endothelial function, which results in reduced cardiac necrosis.

[1]  A. M. Lefer,et al.  Sialyl Lewisx-containing oligosaccharide attenuates myocardial reperfusion injury in cats. , 1994, The Journal of clinical investigation.

[2]  M. Weisfeldt,et al.  Soluble Complement Receptor Type 1 Inhibits the Complement Pathway and Prevents Contractile Failure in the Postischemic Heart Evidence That Complement Activation Is Required for Neutrophil‐Mediated Reperfusion Injury , 1993, Circulation.

[3]  A. M. Lefer,et al.  Monoclonal Antibody to L‐Selectin Attenuates Neutrophil Accumulation and Protects Ischemic Reperfused Cat Myocardium , 1993, Circulation.

[4]  A. M. Lefer,et al.  In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. , 1993, The Journal of clinical investigation.

[5]  R. Virmani,et al.  Myocardial infarct extension during reperfusion after coronary artery occlusion: pathologic evidence. , 1993, Journal of the American College of Cardiology.

[6]  M. Weisfeldt,et al.  Evaluation of the Role of Polymorphonuclear Leukocytes on Contractile Function in Myocardial Reperfusion Injury Evidence for Plasma‐Mediated Leukocyte Activation , 1993, Circulation.

[7]  A. M. Lefer,et al.  Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. , 1993, Circulation research.

[8]  W. Dreyer,et al.  Kinetics of C5a release in cardiac lymph of dogs experiencing coronary artery ischemia-reperfusion injury. , 1992, Circulation research.

[9]  John I. Gallin,et al.  Inflammation: Basic Principles and Clinical Correlates , 1992 .

[10]  A. M. Lefer,et al.  Coronary Endothelial and Cardiac Protective Effects of a Monoclonal Antibody to Intercellular Adhesion Molecule‐1 in Myocardial Ischemia and Reperfusion , 1992, Circulation.

[11]  B. Lucchesi,et al.  Effects of complement activation in the isolated heart. Role of the terminal complement components. , 1992, Circulation research.

[12]  M. Hess,et al.  The oxygen free radical system: from equations through membrane-protein interactions to cardiovascular injury and protection. , 1992, Cardiovascular research.

[13]  A. Varki.  Selectins and other mammalian sialic acid-binding lectins. , 1992 .

[14]  E. Butcher.  Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversity , 1991, Cell.

[15]  I. Sheiban,et al.  Chronic ischaemic ('hibernating') and postischaemic ('stunned') dysfunctional but viable myocardium. , 1991, European heart journal.

[16]  A. M. Lefer,et al.  Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. , 1991, The Journal of clinical investigation.

[17]  J. Olweus,et al.  Blood Flow Regulation During Acute Regional Ischemia in Feline Hearts: Importance of Postjunctional α1- and α1-Adrenoceptors , 1991 .

[18]  A. A. Taylor,et al.  Inflammation in the course of early myocardial ischemia , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  P. Kubes,et al.  Nitric oxide: an endogenous modulator of leukocyte adhesion. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. M. Lefer,et al.  Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  G. Zimmerman,et al.  Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils , 1991, The Journal of cell biology.

[22]  J. Platt,et al.  Neutrophil adhesion to xenogeneic endothelium via iC3b. , 1991, Journal of immunology.

[23]  A. M. Lefer,et al.  Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. , 1990, Circulation.

[24]  B. Fleming,et al.  A method for isolation and fluorescent labeling of rat neutrophils for intravital microvascular studies. , 1990, Microvascular research.

[25]  G. R. Carson,et al.  Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. , 1990, Science.

[26]  R. Virmani,et al.  Mechanisms and therapy of myocardial reperfusion injury. , 1990, Circulation.

[27]  R. Engler,et al.  Thromboxane A2 and peptidoleukotrienes contribute to the myocardial ischemia and contractile dysfunction in response to intracoronary infusion of complement C5a in pigs. , 1990, Circulation research.

[28]  W. Dreyer,et al.  Canine Neutrophil Activation by Cardiac Lymph Obtained During Reperfiision of Ischemic Myocardium , 1989, Circulation research.

[29]  R. Bolli,et al.  Marked Reduction of Free Radical Generation and Contractile Dysfunction by Antioxidant Therapy Begun at the Time of Reperfusion Evidence That Myocardial "Stunning" Is a Manifestation of Reperfusion Injury , 1989, Circulation research.

[30]  P. Sims,et al.  Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. , 1989, The Journal of biological chemistry.

[31]  L. McManus,et al.  Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. , 1988, Circulation.

[32]  M. Entman,et al.  Mechanism of Complement Activation After Coronary Artery Occlusion: Evidence That Myocardial Ischemia in Dogs Causes Release of Constituents of Myocardial Subcellular Origin That Complex With Human C1q In Vivo , 1988, Circulation research.

[33]  D. Mathey,et al.  Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. , 1986, Journal of immunology.

[34]  W. Seeger,et al.  Noncytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B4 generation in human polymorphonuclear leukocytes. , 1986, Journal of immunology.

[35]  M. Shuman,et al.  Immunohistochemical localization of membrane and alpha-granule proteins in human megakaryocytes: application to plastic-embedded bone marrow biopsy specimens. , 1986, Blood.

[36]  K. Mullane,et al.  Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. , 1985, Journal of pharmacological methods.

[37]  A. Campbell,et al.  Monoclonal antibodies demonstrate protection of polymorphonuclear leukocytes against complement attack , 1985, Nature.

[38]  M. Entman,et al.  Selective Accumulation of the First Component of Complement and Leukocytes in Ischemic Canine Heart Muscle: A Possible Initiator of an Extra Myocardial Mechanism of Ischemic Injury , 1985, Circulation research.

[39]  M. Schork,et al.  Reduction of the Extent of Ischemic Myocardial Injury by Neutrophil Depletion in the Dog , 1983, Circulation.

[40]  D. Priebat,et al.  Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. , 1982, The Journal of investigative dermatology.

[41]  M. Chiariello,et al.  Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. , 1978, The Journal of clinical investigation.

[42]  S. Rosalki.  An improved procedure for serum creatine phosphokinase determination. , 1967, The Journal of laboratory and clinical medicine.

[43]  A. Gornall,et al.  Determination of serum proteins by means of the biuret reaction. , 1949, The Journal of biological chemistry.

[44]  A. Weyrich,et al.  Isolated cardiac myocytes are sensitized by hypoxia-reoxygenation to neutrophil-released mediators. , 1994, The American journal of physiology.

[45]  A. M. Lefer,et al.  Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock. , 1993, Annual review of pharmacology and toxicology.

[46]  M. Curtis.  Immunopharmacology of the heart , 1993 .

[47]  G. Zimmerman,et al.  Endothelial cell interactions with granulocytes: tethering and signaling molecules. , 1992, Immunology today.

[48]  R. Olsen,et al.  Demonstration of depressed polymorphonuclear leukocyte function in nonviremic FeLV-infected cats. , 1986, Cancer investigation.